Submission of unaudited (Stanalone) Financials results of (Johnson Pharmacare Limited) for the quarter ended on 31st December 2025 along with limited Review Report Thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Johnson Pharmacare Limited has submitted its unaudited standalone results for the quarter ended 31 December 2025. The company reported zero revenue from operations and zero other income for Q3 FY26, continuing a trend of no business activity across all reported periods. Total expenses for the quarter stood at Rs. 6.40 lakhs, driven mainly by finance costs of Rs. 4.01 lakhs and other expenses of Rs. 2.18 lakhs, resulting in a net loss of Rs. 6.40 lakhs for the quarter. For the nine months ended December 2025, the cumulative loss widened to Rs. 12.34 lakhs versus Rs. 7.06 lakhs in the same period last year. The paid-up equity share capital remains at Rs. 5,500 lakhs (face value Rs. 1). The statutory auditor VRSK & Associates issued a limited review report containing an Emphasis of Matter paragraph.
The company continues to show no operational revenue and is incurring losses funded by finance costs, raising concerns about its business viability. Shareholders should view this as a distressed, non-operating entity with negligible equity earnings (basic EPS at essentially zero), though the small absolute loss amounts mean the direct cash impact per share is minimal. The auditor's Emphasis of Matter warrants attention as it flags an issue management has drawn attention to in the financial review.